Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Psychiatrists at any stage in their training in the UK who wish to do a DPhil (PhD) can apply for this prestigious scheme which pays an appropriate clinical salary, fees, and research costs, for three years. Up to four places are available.

We are looking for the next generation of academic psychiatrists. Full details of the programme, potential supervisors, example projects, and how to apply, can be found here.

Fellows will receive training in a range of methods, and will conduct research leading to the award of a D.Phil. in their chosen area. Fellowships are for three years and include fees, clinical salary, and support for research costs. The programme places strong emphasis on translational research, and Fellows will have the opportunity to spend a day a week in a clinical unit specialising in translating research findings into routine care.

The deadline for applications is 8 January 2016 but you are advised to contact potential supervisors as soon as possible to discuss the scheme and develop a suitable project. Successful candidates will start in Autumn 2016. However, You can also contact Professor Paul Harrison (paul.harrison@psych.ox.ac.uk) for advice and further information.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.